Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)

NCT04844918 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04844918
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04844918 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
May 10, 2021
Completion date
June 24, 2023
Enrollment
267 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

obesity